Vivian Rexroad, PharmD

CRS:

JHU

Role:

Pharmacy

Position:

Pharmacist, PharmD, Investigational Drug Pharmacy

Email:

vrexroa@jhmi.edu
  • Network Pharmacist, IMPAACT Leadership
  • Member, IMPAACT Multidisciplinary Protocol Review Group
  • Protocol team member for IMPAACT 1078, IMPAACT 1114,  IMPAACT 2000 and IMPAACT 2011
  • General Member (Pharmacist), Protocol Development and Implementation Subcommittee of the SMCCC (Mar 2016-Nov 2019)
  • Member, Pharmacy Working Group of the Protocol Development and Implementation Subcommittee (Mar 2016-Nov 2019)
  • Protocol team member, IMPAACT 2012
  • Protocol team member, IMPAACT 2013
  • Protocol team member, IMPAACT 2018
  • Protocol team member, IMPAACT 2021

Categories

Leadership Committees
CRS
Roles

Clinical Trials

NWCS 414, Evaluation of a Serum Biosignature for Identifying...

We will address our hypothesis using a case-control study design. We plan to leverage the existing biorepository of...

Read More

A5314: Effect of LDMTX on Inflammation in HIV-infected...

A5314 is a phase II randomized, double-blind, placebo-controlled 36-week trial that will examine the safety and efficacy of...

Read More

ACTIV-2/A5401: Adaptive Platform Treatment for Outpatients...

Rationale: There is an urgent need for a platform to rapidly evaluate therapies in the outpatient setting, to prevent disease...

Read More

P1078: A Phase IV Randomized Double-Blind Placebo-Controlled...

P1078 is a Phase IV, randomized, double-blind, placebo-controlled study of HIV-infected pregnant women and the infants born to...

Read More

A5342: Evaluating the Safety, Tolerability, and Effect of a...

The purpose of this study is to evaluate the safety, tolerability, and effect of an experimental human monoclonal antibody...

Read More